Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHIRON VACCINE FOR AIDS COULD BE AVAILABLE FOR TESTING "WITHIN A YEAR,"

Executive Summary

CHIRON VACCINE FOR AIDS COULD BE AVAILABLE FOR TESTING "WITHIN A YEAR," following the successful cloning of the genetic material of the virus thought to be the causal agent of AIDS (Acquired Immune Deficiency Syndrome), the company said. In addition, Chiron said that its AIDS work "is expected to lead to the development of a safe and cost effective blood test for diagnosing the disease," which the company estimated could be commercially available in six to eight weeks. In a Sept. 10 press announcement, Chiron reported that it has cloned the genome for the AIDS associated retrovirus (ARV). Chiron said that it believes ARV could be the same virus as HTLV-III, identified by Natl. Institute of Health researchers as being associated with AIDS, and the LAV virus discovered by scientists at the Pasteur Institute in France. Chiron was one of the approximately 15 companies whose applications to NIH for use of HTLV-III were turned down. As a result, Chiron approached Jay Levy, MD, University of California, San Francisco, for access to ARV. The five companies to win HTLV-III development rights were Abbott, DuPont, Litton Bionetics, Electro-Nucleonics, and Travenol Genentech Diagnostics. The Emeryville, Calif.-based biotech firm has already successfully developed an rDNA-derived hepatitis B vaccine for Merck that is currently undergoing Phase III testing and a feline leukemia virus (FeLV) vaccine. Chiron said that it believes that "the expertise gained in the production of both the hepatitis B and FeLV vaccines will be advantageous in approaching the problem of development of a vaccine to prevent AIDS." The AIDS vaccine work is one of over 20 ongoing R&D projects at Chiron, including development of rDNA-derived blood factor VIII, tissue plasminogen activator, human growth hormone and vaccines for herpes, hepatitis A, and hepatitis non-A, non-B. In addition, Chiron's genetically produced human epidermal growth factor is now moving into Phase II clinicals for promotion of healing after corneal transplant surgery and other catastrophic eye diseases.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel